310 related articles for article (PubMed ID: 27402915)
1. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
[TBL] [Abstract][Full Text] [Related]
2. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.
Papamichael K; Van Stappen T; Vande Casteele N; Gils A; Billiet T; Tops S; Claes K; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):543-9. PubMed ID: 26681486
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis.
Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C
Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
5. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
[TBL] [Abstract][Full Text] [Related]
7. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
8. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
Baert F; Vande Casteele N; Tops S; Noman M; Van Assche G; Rutgeerts P; Gils A; Vermeire S; Ferrante M
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1324-32. PubMed ID: 25277873
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
[TBL] [Abstract][Full Text] [Related]
12. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
13. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
[TBL] [Abstract][Full Text] [Related]
16. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
17. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
[TBL] [Abstract][Full Text] [Related]
18. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
de Bruyn M; Ringold R; Martens E; Ferrante M; Van Assche G; Opdenakker G; Dukler A; Vermeire S
J Crohns Colitis; 2020 Feb; 14(2):176-184. PubMed ID: 31628842
[TBL] [Abstract][Full Text] [Related]
19. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
[TBL] [Abstract][Full Text] [Related]
20. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients.
Miyoshi J; Matsuoka K; Inoue N; Hisamatsu T; Ichikawa R; Yajima T; Okamoto S; Naganuma M; Sato T; Kanai T; Ogata H; Iwao Y; Hibi T
J Crohns Colitis; 2013 Dec; 7(12):e609-14. PubMed ID: 23680174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
